Distribution agreement with Ravenswood for SlimBiome®
Our Commercial Strategy is founded on a strong scientific approach to target large markets with unmet needs, delivered by working in partnership.
Products aimed at large (>£100m), growing markets
All activities underpinned by scientific approach
Partner with food,
health and well being companies
Scalable business model and technology platforms
The business is structured in four divisions that creates the platform for growth and future corporate options.
Each of the divisions has potential to target a number of segments and market opportunities that could be scalable in their own right.
Where relevant, IP that is applicable across a number of applications is held centrally and licensed to the divisions.
Progress across all Platforms
There has been sustained momentum across all platforms:
- Increased R&D expenditure offset by joint development income
- Substantive increase in IP portfolio
- Five to 11 patents
- Three to eight strain registrations
- Three to seven trademarks
- Commercial agreements in each platform
ProBiotix Health anticipating "big commercial opportunities" during 2023
Group CEO Stephen O’Hara and CEO Steen Anderson | 04 January 2023